Ocugen's latest update left its fair value estimate near $9.00 per share and revenue growth outlook largely intact, even as analyst sentiment turned slightly more cautious. A barely noticeable trim to ...

Ocugen ( ($OCGN) ) has issued an update. In the fourth quarter of 2025, Ocugen’s Board, following a review by its Compensation Committee and ...

Investors might want to bet on Ocugen (OCGN), as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the ...

Good morning, and welcome to Ocugen's Third Quarter 2025 Financial Results and Business Update. Please note that this call is being recorded at this time. [Operator Instructions] I will now turn the ...

Ocugen (OCGN) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to a loss of $0.05 per share a year ago. These figures are ...

Shares of biotechnology firm Ocugen are currently caught between conflicting market signals. While the stock's price action ...

The stock's fall snapped a six-day winning streak.

Ocugen is focused on developing treatments for vision-threatening diseases. Its main focus is gene therapy, a technique that uses genetic material to treat or prevent disease. The company's lead gene ...

Ocugen Inc. closed 24.21% short of its 52-week high of $1.90, which the company reached on October 3rd.

Bank of New York Mellon Corp grew its holdings in shares of Ocugen, Inc. (NASDAQ:OCGN – Free Report) by 7.8% during the first quarter, according to its most recent 13F filing with the SEC. The ...

MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) announced it has entered into a securities purchase agreement with Janus Henderson Investors for a registered direct offering valued at approximately $20 ...

From 2012 (when our Director of Research Sheraz Mian assumed responsibility for the portfolio) through November, 2025, the Zacks Top 10 Stocks gained +2,530.8%, more than QUADRUPLING the S&P 500’s ...